These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 8794414

  • 1. The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
    Trillet-Lenoir V, Soler P, Arpin D, Bohas C, Riou R, Court-Fortune I, Ecochard D, Perol M, Cordier JF.
    Lung Cancer; 1996 Jun; 14(2-3):331-41. PubMed ID: 8794414
    [Abstract] [Full Text] [Related]

  • 2. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
    Hanauske AR, Korfel A, Perker M, Heinrich B, Schwab G, Graf M, Depenbrock H, Höffken G, Kreuser ED, Thiel E, Zwingers T, Berdel WE.
    Oncology; 1997 Jun; 54(5):363-70. PubMed ID: 9260596
    [Abstract] [Full Text] [Related]

  • 3. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
    Thatcher N, Clark PI, Smith DB, Anderson H, Girling DJ, Machin D, Stephens RJ, Lallemand G, Jenkins B.
    Clin Oncol (R Coll Radiol); 1995 Jun; 7(5):293-9. PubMed ID: 8580054
    [Abstract] [Full Text] [Related]

  • 4. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N.
    J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
    [Abstract] [Full Text] [Related]

  • 5. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
    Veldhuis GJ, Willemse PH, Beijnen JH, Boonstra H, Piersma H, van der Graaf WT, de Vries EG.
    Br J Cancer; 1997 Mar; 75(5):703-9. PubMed ID: 9043028
    [Abstract] [Full Text] [Related]

  • 6. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
    Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, Humblet Y, Bosquée L, Pasini F, Marangolo M.
    J Clin Oncol; 1999 Nov; 17(11):3531-9. PubMed ID: 10550151
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
    Bronchud M, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM.
    Behring Inst Mitt; 1988 Aug; (83):327-9. PubMed ID: 2467655
    [Abstract] [Full Text] [Related]

  • 8. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL, Valone FH, Herndon JE, Crawford J, Richards F, Rege VB, Clamon G, Green MR.
    Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
    [Abstract] [Full Text] [Related]

  • 9. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK, Blatt J, Blazar BR, Frierdich S, Liu-Mares W, Reaman GH.
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
    [Abstract] [Full Text] [Related]

  • 10. Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
    Hastürk S, Kurt B, Kocabas A, Orüç O, Burgut R.
    J Chemother; 1997 Feb; 9(1):66-71. PubMed ID: 9106021
    [Abstract] [Full Text] [Related]

  • 11. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
    Ardizzoni A, Venturini M, Crinò L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R.
    Eur J Cancer; 1993 Feb; 29A(5):687-92. PubMed ID: 8385970
    [Abstract] [Full Text] [Related]

  • 12. Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
    Skarlos DV, Samantas E, Pectasides D, Pavlidis N, Kalofonos C, Klouvas G, Panoussaki E, Tsiakopoulos E, Poulakis N, Fountzilas G.
    Am J Clin Oncol; 1999 Feb; 22(1):87-93. PubMed ID: 10025390
    [Abstract] [Full Text] [Related]

  • 13. r-metHuG-CSF support to ifosfamide, cisplatin, etoposide chemotherapy in non-small cell lung cancer.
    Gautier V, Pujol JL, Zinaï A, Michel FB.
    Lung Cancer; 1996 Jun; 14(2-3):343-51. PubMed ID: 8794415
    [Abstract] [Full Text] [Related]

  • 14. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
    Crawford J, George M.
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
    [Abstract] [Full Text] [Related]

  • 15. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

  • 16. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
    Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ.
    J Clin Oncol; 2000 Jan; 18(2):395-404. PubMed ID: 10637255
    [Abstract] [Full Text] [Related]

  • 17. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
    Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG.
    J Clin Oncol; 1994 Jan; 12(1):77-82. PubMed ID: 7505809
    [Abstract] [Full Text] [Related]

  • 18. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W, Birken R, Bertz H, Hecht T, Pressler K, Frisch J, Schulz G, Mertelsmann R, Kanz L.
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [Abstract] [Full Text] [Related]

  • 19. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R.
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
    Thongprasert S.
    J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.